From 762f4f8661ed10c9d1b26d9824a9ee6c7421146e Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Tue, 20 Feb 2024 11:23:07 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web___Update 2024___02.md | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/pages/STOP2030___Web___Update 2024___02.md b/pages/STOP2030___Web___Update 2024___02.md index 40277978..191c987f 100644 --- a/pages/STOP2030___Web___Update 2024___02.md +++ b/pages/STOP2030___Web___Update 2024___02.md @@ -53,7 +53,7 @@ - ## Objetivos y logros de los proyectos STOP previos (en background) - Qualification at EMA for art. 58 - Safety of IVM up to 600μg/kg alone and in coformulation with albendazole - - Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa + - Demonstrated efficacy against T. trichiura in a pivotal trial in Sub-Saharan Africa - No stopping rules were reached - Safety was adequate - Palatability results confirm adecuacy of size, taste and smell @@ -85,4 +85,4 @@ - ## HOME - ### Background - Especificar que la novel formulation es una fixed-dose coformulation de [[Ivermectina]] y [[Albendazol]]. - - Especificar que esta fixed-dose coformulation de ivm/alb es la lower \ No newline at end of file + - Especificar que esta fixed-dose coformulation de ivm/alb has the lowest level of investment risk of all candidates for Combi \ No newline at end of file